Continuous Glucose Monitoring Systems Market by Component, Demographics, Patient Type, End User, Distribution Channel

Description

List of Tables

[191 Pages Report] The Continuous Glucose Monitoring Systems Market size was estimated at USD 5.54 billion in 2023 and expected to reach USD 6.21 billion in 2024, at a CAGR 12.37% to reach USD 12.55 billion by 2030.

Continuous Glucose Monitoring Systems (CGMS) are advanced medical devices designed to provide real-time glucose readings at regular intervals, typically every few minutes, 24/7. These systems comprise a small sensor that transmits the data wirelessly to a display device, which could be a dedicated receiver, a smartphone, or a smartwatch, enabling the user to monitor their glucose levels without the requirement of traditional fingerstick blood tests. The growing preponderance of diabetes across the globe and the rising awareness of the benefits of continuous glucose monitoring over traditional blood glucose monitoring are driving the market growth. However, devices' high prices and lack of uniform reimbursement can limit market penetration. Inaccuracies in glucose readings due to device calibration issues or interference from external factors also pose a challenge. Furthermore, leveraging big data and advanced analytics to improve predictive capabilities, personalization, and clinical outcomes creates potential opportunities for market growth.

KEY MARKET STATISTICS
Base Year [2023]	USD 5.54 billion
Estimated Year [2024]	USD 6.21 billion
Forecast Year [2030]	USD 12.55 billion
CAGR (%)	12.37%

Component: Increasing utilization of transmitters & receivers in CGM systems for real-time glucose monitoring

Integrated insulin pumps are devices that deliver insulin automatically based on the set basal rate and work in conjunction with continuous glucose monitoring (CGM) systems. They adjust the insulin delivery based on real-time glucose readings. This feature greatly contributes to the seamless management of blood glucose levels in diabetes patients, especially useful for those with intensive insulin therapy needs or those with Type 1 diabetes. Sensors are a crucial part of CGM systems, as they are the components that measure levels of glucose in the interstitial fluid beneath the skin. CGM sensors typically require changing every 7 to 14 days, depending on the model. Patients who desire minimal intrusion and longer wear times prefer sensors with extended life spans. The transmitter is the part of the CGM system that sends real-time glucose data from the sensor to a receiver and smart device. The receiver is the device that displays the glucose data. Some patients prioritize a system that allows the use of their own smartphone as a receiver, whereas others prefer a dedicated device if they are not comfortable using smart devices.

Demographics: Ongoing advancements in children CGM systems to make it more effective and less invasive

Continuous Glucose Monitoring (CGM) systems are crucial for the adult population, especially those diagnosed with Type 1 or Type 2 diabetes. Adults require consistent and accurate monitoring of their blood glucose levels to manage their condition effectively and to prevent acute and long-term complications associated with diabetes. CGM systems for children are designed with special considerations for size, sensitivity, and ease of use, owing to the unique physiological and lifestyle requirements of the pediatric population. These devices help parents and caregivers monitor and manage their child's diabetes more effectively, providing peace of mind and improved quality of life.

Patient Type: Rising significance of CGM system in Type 1 diabetes patient for high accuracy, minimal lag time, and predictive alerts for rapid glucose changes

Patients with Type 1 diabetes rely on external insulin because of the autoimmune destruction of the insulin-producing beta cells in the pancreas. Continuous Glucose Monitoring (CGM) systems for this group provide convenience and crucial tools for the management of glucose levels. These patients need real-time data to adjust insulin doses accurately. CGM systems offer significant advantages over traditional blood glucose monitoring, providing detailed insights into glucose trends, which results in better glycemic control and reduction of hypoglycemia risk. Type 2 diabetes patients might not always require insulin but still need to monitor their glucose levels, especially if they are on sulfonylureas and meglitinides, which increase the risk of hypoglycemia. CGM for Type 2 diabetes is geared towards lifestyle management, including diet and exercise, alongside medication. The use of CGM is progressively becoming more common in this group as the technology becomes more affordable and as evidence mounts that it can help improve glycemic control in non-insulin-treated patients.

End User: Growing preference of CGM systems by home patients with remote data sharing capabilities

Diagnostic centers and clinics represent a significant segment for the deployment of Continuous Glucose Monitoring (CGM) systems. These facilities often serve as the initial point of contact for patients experiencing symptoms of diabetes and for those who require ongoing monitoring for their diagnosed condition. Home healthcare represents a rapidly growing segment for CGM systems, as an increasing number of patients with diabetes prefer to manage their condition in the comfort of their own homes. These devices offer convenience and allow for continuous monitoring without the need to visit a healthcare provider frequently. Intensive Care Units (ICUs) are critical settings wherein patients require constant and close monitoring, including for their glucose levels. CGM systems in ICUs must be highly reliable and capable of integrating with other monitoring equipment to ensure a holistic view of a patient's health status.

Regional Insights

The Americas, led by the United States and Canada, show a strong market for CGM systems, aided by higher purchasing power and well-established healthcare systems implementing the latest technologies. The United States & Canada are prominent in CGM technology, with numerous companies researching and developing new systems, evident from a high number of patents filed in this domain. Consumers in the United States have shown an inclination towards maintaining healthy lifestyles, integrating personal health technology with everyday living. There is significant investment and insurance coverage that promotes the use of CGM systems, making them more accessible to the population. European Union countries demonstrate a robust demand for CGM systems, broadly supported by widespread awareness, a push for lifestyle management of diabetes, and favorable insurance reimbursement scenarios. The European Union's medical device sector is tightly regulated, ensuring high standards of product quality and safety. Countries including Germany, France, and the UK are leaders in the adoption of CGM systems. The Middle East, particularly the Gulf Cooperation Council (GCC) countries, has high per capita healthcare spending and is rapidly adopting advanced technologies in healthcare. Asia Pacific is undergoing a surge in the demand for CGM systems due to the increasing prevalence of diabetes and heightened awareness about the disease. The rising popularity of wearable technology for health monitoring indicates a broad consumer need for convenient and non-intrusive healthcare devices in the APAC region.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Continuous Glucose Monitoring Systems Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Continuous Glucose Monitoring Systems Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Continuous Glucose Monitoring Systems Market, highlighting leading vendors and their innovative profiles. These include A. Menarini Diagnostics s.r.l, Abbott Laboratories, AgaMatrix Inc. by I-Sens Inc., Ascensia Diabetes Care Holdings AG, Dexcom, Inc., F. Hoffmann-La Roche Ltd., Insulet Corporation, Johnson & Johnson Services, Inc., Medtronic PLC, Medtrum Technologies Inc., Nemaura Medical Inc., Novo Nordisk A/S, NXP Semiconductors N.V., Senseonics Holdings Inc., Sibionics, STMicroelectronics N.V., Tandem Diabetes Care, Inc., Texas Instruments Incorporated, and Ypsomed Holding AG.

Market Segmentation & Coverage

This research report categorizes the Continuous Glucose Monitoring Systems Market to forecast the revenues and analyze trends in each of the following sub-markets:

Component
- Integrated Insulin Pumps
- Sensors
- Transmitters & Receivers

Demographics
- Adult Population
- Children Population

Patient Type
- Type 1 Diabetes
- Type 2 Diabetes

End User
- Diagnostic Centers & Clinics
- Home Healthcare
- ICUs

Distribution Channel
- Institutional Sales
- Retail Sales

Region
- Americas
  - Argentina
  - Brazil
  - Canada
  - Mexico
  - United States
    - California
    - Florida
    - Illinois
    - New York
    - Ohio
    - Pennsylvania
    - Texas
- Asia-Pacific
  - Australia
  - China
  - India
  - Indonesia
  - Japan
  - Malaysia
  - Philippines
  - Singapore
  - South Korea
  - Taiwan
  - Thailand
  - Vietnam

Europe, Middle East & Africa
- Denmark
- Egypt
- Finland
- France
- Germany
- Israel
- Italy
- Netherlands
- Nigeria
- Norway
- Poland
- Qatar
- Russia
- Saudi Arabia
- South Africa
- Spain
- Sweden
- Switzerland
- Turkey
- United Arab Emirates
- United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Continuous Glucose Monitoring Systems Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Continuous Glucose Monitoring Systems Market?

3. What are the technology trends and regulatory frameworks in the Continuous Glucose Monitoring Systems Market?

4. What is the market share of the leading vendors in the Continuous Glucose Monitoring Systems Market?

5. Which modes and strategic moves are suitable for entering the Continuous Glucose Monitoring Systems Market?

Product Code: MRR-43676CF422F8

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Increasing Number of Incidence of Diabetic Patients Globally
  - 5.1.1.2. Growing Regulatory Approvals for the CGM Systems
  - 5.1.1.3. Growing Adoption Rate of CGM Systems in Home Healthcare
- 5.1.2. Restraints
  - 5.1.2.1. Occurrence of Adverse Effects and Limited Accuracy of CGM Devices
- 5.1.3. Opportunities
  - 5.1.3.1. Technological Advancements and Increased Awareness of CGM Systems
  - 5.1.3.2. Rising Preferences for Non-invasive Methods and Potential Undiagnosed Patient Population
- 5.1.4. Challenges
  - 5.1.4.1. Reimbursement and Stringent Regulatory Issues
5.2. Market Segmentation Analysis
- 5.2.1. Component: Increasing utilization of transmitters & receivers in CGM systems for real-time glucose monitoring
- 5.2.2. Demographics: Ongoing advancements in children CGM systems to make it more effective and less invasive
- 5.2.3. Patient Type: Rising significance of CGM system in Type 1 diabetes patient for high accuracy, minimal lag time, and predictive alerts for rapid glucose changes
- 5.2.4. End User: Growing preference of CGM systems by home patients with remote data sharing capabilities
5.3. Market Trend Analysis
5.4. Cumulative Impact of Russia-Ukraine Conflict
5.5. Cumulative Impact of High Inflation
5.6. Porter's Five Forces Analysis
- 5.6.1. Threat of New Entrants
- 5.6.2. Threat of Substitutes
- 5.6.3. Bargaining Power of Customers
- 5.6.4. Bargaining Power of Suppliers
- 5.6.5. Industry Rivalry
5.7. Value Chain & Critical Path Analysis
5.8. Regulatory Framework Analysis
5.9. Client Customization

6. Continuous Glucose Monitoring Systems Market, by Component

6.1. Introduction
6.2. Integrated Insulin Pumps
6.3. Sensors
6.4. Transmitters & Receivers

7. Continuous Glucose Monitoring Systems Market, by Demographics

7.1. Introduction
7.2. Adult Population
7.3. Children Population

8. Continuous Glucose Monitoring Systems Market, by Patient Type

8.1. Introduction
8.2. Type 1 Diabetes
8.3. Type 2 Diabetes

9. Continuous Glucose Monitoring Systems Market, by End User

9.1. Introduction
9.2. Diagnostic Centers & Clinics
9.3. Home Healthcare
9.4. ICUs

10. Continuous Glucose Monitoring Systems Market, by Distribution Channel

10.1. Introduction
10.2. Institutional Sales
10.3. Retail Sales

11. Americas Continuous Glucose Monitoring Systems Market

11.1. Introduction
11.2. Argentina
11.3. Brazil
11.4. Canada
11.5. Mexico
11.6. United States

12. Asia-Pacific Continuous Glucose Monitoring Systems Market

12.1. Introduction
12.2. Australia
12.3. China
12.4. India
12.5. Indonesia
12.6. Japan
12.7. Malaysia
12.8. Philippines
12.9. Singapore
12.10. South Korea
12.11. Taiwan
12.12. Thailand
12.13. Vietnam

13. Europe, Middle East & Africa Continuous Glucose Monitoring Systems Market

13.1. Introduction
13.2. Denmark
13.3. Egypt
13.4. Finland
13.5. France
13.6. Germany
13.7. Israel
13.8. Italy
13.9. Netherlands
13.10. Nigeria
13.11. Norway
13.12. Poland
13.13. Qatar
13.14. Russia
13.15. Saudi Arabia
13.16. South Africa
13.17. Spain
13.18. Sweden
13.19. Switzerland
13.20. Turkey
13.21. United Arab Emirates
13.22. United Kingdom

14. Competitive Landscape

14.1. Market Share Analysis, 2023
14.2. FPNV Positioning Matrix, 2023
14.3. Competitive Scenario Analysis
- 14.3.1. Sibionics obtains CE Mark for GS1 continuous glucose monitoring system
- 14.3.2. Dexcom targets Americans with new CGM aimed at non-insulin-using diabetics
- 14.3.3. U.S. FDA Clears Abbott's Freestyle Libre 2 and Freestyle Libre 3 Sensors for Integration with Automated Insulin Delivery Systems

15. Competitive Portfolio

15.1. Key Company Profiles
15.2. Key Product Portfolio